Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine industry news items to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.
Nue Life Closes $23 million Series A Financing
Nue Life, a telemedicine startup building a mental wellness platform, has just closed a $23 million Series A equity financing. The raise was led by Obvious Ventures (co-founded by Ev Williams, a co-founder of Twitter) and is a helpful reminder that the long-term potential of the sector hasn’t changed.
Irwin Naturals Acquires Chain of Ketamine Clinics
In March we had the first acquisition of Midwest Ketafusion, a clinic in Iowa City, and yesterday there was the announcement of an acquisition agreement with KHC Capital Group (“Ketamine Health Centers”) and their chain of five ketamine treatment clinics in Florida (with an additional partnership contract with two affiliate clinics in Mexico).
Mindset Pharma Strengthens IP Portfolio with Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds
“The Mindset ‘Family 4’ compounds have shown promise in efficacy and safety at a range of doses compared to first-generation DMT and 5-MeO-DMT compounds based on rodent pre-clinical models. Our strong IP position on this family enhances their commercial viability,” said James Lanthier, CEO of Mindset.
Cybin Announces Partnership for CYB-003 Trial
Cybin’s new partner for their upcoming trial is Clinilabs, a full-service contract research organization (CRO) focused exclusively on central nervous system drug development…and has conducted more than 675 CNS clinical trials in our 21-year history and played a pivotal role in the approval of 19 new therapies across 10 CNS indications.
MYND Life Sciences Announces $3.5 Million Share Offering
The company plans to undertake a non-brokered private placement offering of common shares to raise gross proceeds of a minimum of $3,000,000 up to $3,500,000.
Psyence and Filament Health Enter Into Exclusive Licensing Agreement for Natural Psilocybin Products
The partnership leverages Psyence’s expertise in fungi cultivation and palliative care as well as Filament’s expertise in the manufacture of pharmaceutical grade drug candidates.
Dr. Neil Maresky, Chief Executive Officer of Psyence. “Partnering with Filament is a perfect complement to our expertise in both the cultivation and delivery of these substances to patients in need as we commence our palliative care clinical trial. Licensing Filament’s IP and leveraging their data and experience will allow us to expedite our UK clinical trial application.”
